Loading...
XLON
PRM
Market cap6mUSD
Jul 10, Last price  
1.70GBP
1D
0.00%
1Q
7.59%
Jan 2017
-69.09%
Name

Proteome Sciences PLC

Chart & Performance

D1W1MN
XLON:PRM chart
P/E
—
P/S
1.31
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-4.43%
Revenues
4m
-23.14%
68,469265,593849,4871,305,69401,021,1661,152,9672,136,6811,560,7151,882,0002,744,0003,380,0003,049,0004,634,0004,712,0005,124,0007,780,0005,028,0004,887,0003,756,000
Net income
-3m
L-10.13%
-5,637,690-5,252,029-4,624,468-4,009,8304,563,163-3,957,341-4,253,594-3,149,159-3,566,481-2,718,000-2,280,000-2,497,000-1,313,000149,000295,00072,0001,325,000-2,443,000-3,406,000-3,061,000
CFO
-46k
L-94.43%
-3,606,000-4,093,000-4,122,000-2,972,0004,003,000-5,166,000-3,353,367-11,550,000,000-6,267,000,00046,633,000,000-31,695,000,00055,473,000,000-14,780,000,000-21,451,000,0001,583,000793,0002,140,000-481,000-826,000-46,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Proteome Sciences Plc is a provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Cobham, the United Kingdom.
URL
https://www.proteomics.com/
IPO date
Oct 03, 1995
Employees
27
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT